Thyroid Cancer Among 988 Patients With Histological Confirmations, Stratified by Age Cohort
| Age Cohort . | No. of Patients . | Malignant, n (%) . | Type of Malignancy . | |
|---|---|---|---|---|
| Well-Differentiated Thyroid Carcinoma, n (%)a . | High-Risk Thyroid Carcinoma, n (%)a . | |||
| 20–29 y | 420 | 93 (22) | 93 (100) | 0 (0) |
| ■ 79 PTC | ■ 0 Anaplastic/poorly diff | |||
| ■ 14 FTC | ■ 0 MTC | |||
| ■ 0 DMC | ||||
| 30–39 y | 908 | 191 (21) | 187 (97.9) | 4 (2.1) |
| ■ 170 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 17 FTC | ■ 1 MTC | |||
| ■ 1 DMC | ||||
| 40–49 y | 1475 | 246 (17) | 240 (97.6) | 6 (2.4) |
| ■ 224 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 16 FTC | ■ 3 MTC | |||
| ■ 1 DMC | ||||
| 50–59 y | 1606 | 204 (13) | 195 (96.0) | 9 (4.4) |
| ■ 178 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 17 FTC | ■ 4 MTC | |||
| ■ 3 DMC | ||||
| 60–69 y | 1209 | 163 (13) | 142 (87.1) | 21 (12.9) |
| ■ 128 PTC | ■ 12 Anaplastic/poorly diff | |||
| ■ 14 FTC | ■ 1 MTC | |||
| ■ 8 DMC | ||||
| >70 y | 773 | 94 (12) | 79 (84.0) | 15 (15.9) |
| ■ 72 PTC | ■ 9 Anaplastic/poorly diff | |||
| ■ 7 FTC | ■ 1 MTC | |||
| ■ 5 DMC | ||||
| Age Cohort . | No. of Patients . | Malignant, n (%) . | Type of Malignancy . | |
|---|---|---|---|---|
| Well-Differentiated Thyroid Carcinoma, n (%)a . | High-Risk Thyroid Carcinoma, n (%)a . | |||
| 20–29 y | 420 | 93 (22) | 93 (100) | 0 (0) |
| ■ 79 PTC | ■ 0 Anaplastic/poorly diff | |||
| ■ 14 FTC | ■ 0 MTC | |||
| ■ 0 DMC | ||||
| 30–39 y | 908 | 191 (21) | 187 (97.9) | 4 (2.1) |
| ■ 170 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 17 FTC | ■ 1 MTC | |||
| ■ 1 DMC | ||||
| 40–49 y | 1475 | 246 (17) | 240 (97.6) | 6 (2.4) |
| ■ 224 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 16 FTC | ■ 3 MTC | |||
| ■ 1 DMC | ||||
| 50–59 y | 1606 | 204 (13) | 195 (96.0) | 9 (4.4) |
| ■ 178 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 17 FTC | ■ 4 MTC | |||
| ■ 3 DMC | ||||
| 60–69 y | 1209 | 163 (13) | 142 (87.1) | 21 (12.9) |
| ■ 128 PTC | ■ 12 Anaplastic/poorly diff | |||
| ■ 14 FTC | ■ 1 MTC | |||
| ■ 8 DMC | ||||
| >70 y | 773 | 94 (12) | 79 (84.0) | 15 (15.9) |
| ■ 72 PTC | ■ 9 Anaplastic/poorly diff | |||
| ■ 7 FTC | ■ 1 MTC | |||
| ■ 5 DMC | ||||
Abbreviations: PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; Anaplastic/poorly diff, anaplastic or poorly differentiated thyroid cancer; MTC, medullary thyroid carcinoma; DMC, distant metastatic carcinoma. The proportion of well-differentiated thyroid carcinoma (papillary or follicular carcinoma) vs high-risk thyroid carcinoma (anaplastic, medullary, poorly differentiated, or distant metastatic carcinoma) is shown.
P < .001 for trend.
Thyroid Cancer Among 988 Patients With Histological Confirmations, Stratified by Age Cohort
| Age Cohort . | No. of Patients . | Malignant, n (%) . | Type of Malignancy . | |
|---|---|---|---|---|
| Well-Differentiated Thyroid Carcinoma, n (%)a . | High-Risk Thyroid Carcinoma, n (%)a . | |||
| 20–29 y | 420 | 93 (22) | 93 (100) | 0 (0) |
| ■ 79 PTC | ■ 0 Anaplastic/poorly diff | |||
| ■ 14 FTC | ■ 0 MTC | |||
| ■ 0 DMC | ||||
| 30–39 y | 908 | 191 (21) | 187 (97.9) | 4 (2.1) |
| ■ 170 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 17 FTC | ■ 1 MTC | |||
| ■ 1 DMC | ||||
| 40–49 y | 1475 | 246 (17) | 240 (97.6) | 6 (2.4) |
| ■ 224 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 16 FTC | ■ 3 MTC | |||
| ■ 1 DMC | ||||
| 50–59 y | 1606 | 204 (13) | 195 (96.0) | 9 (4.4) |
| ■ 178 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 17 FTC | ■ 4 MTC | |||
| ■ 3 DMC | ||||
| 60–69 y | 1209 | 163 (13) | 142 (87.1) | 21 (12.9) |
| ■ 128 PTC | ■ 12 Anaplastic/poorly diff | |||
| ■ 14 FTC | ■ 1 MTC | |||
| ■ 8 DMC | ||||
| >70 y | 773 | 94 (12) | 79 (84.0) | 15 (15.9) |
| ■ 72 PTC | ■ 9 Anaplastic/poorly diff | |||
| ■ 7 FTC | ■ 1 MTC | |||
| ■ 5 DMC | ||||
| Age Cohort . | No. of Patients . | Malignant, n (%) . | Type of Malignancy . | |
|---|---|---|---|---|
| Well-Differentiated Thyroid Carcinoma, n (%)a . | High-Risk Thyroid Carcinoma, n (%)a . | |||
| 20–29 y | 420 | 93 (22) | 93 (100) | 0 (0) |
| ■ 79 PTC | ■ 0 Anaplastic/poorly diff | |||
| ■ 14 FTC | ■ 0 MTC | |||
| ■ 0 DMC | ||||
| 30–39 y | 908 | 191 (21) | 187 (97.9) | 4 (2.1) |
| ■ 170 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 17 FTC | ■ 1 MTC | |||
| ■ 1 DMC | ||||
| 40–49 y | 1475 | 246 (17) | 240 (97.6) | 6 (2.4) |
| ■ 224 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 16 FTC | ■ 3 MTC | |||
| ■ 1 DMC | ||||
| 50–59 y | 1606 | 204 (13) | 195 (96.0) | 9 (4.4) |
| ■ 178 PTC | ■ 2 Anaplastic/poorly diff | |||
| ■ 17 FTC | ■ 4 MTC | |||
| ■ 3 DMC | ||||
| 60–69 y | 1209 | 163 (13) | 142 (87.1) | 21 (12.9) |
| ■ 128 PTC | ■ 12 Anaplastic/poorly diff | |||
| ■ 14 FTC | ■ 1 MTC | |||
| ■ 8 DMC | ||||
| >70 y | 773 | 94 (12) | 79 (84.0) | 15 (15.9) |
| ■ 72 PTC | ■ 9 Anaplastic/poorly diff | |||
| ■ 7 FTC | ■ 1 MTC | |||
| ■ 5 DMC | ||||
Abbreviations: PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; Anaplastic/poorly diff, anaplastic or poorly differentiated thyroid cancer; MTC, medullary thyroid carcinoma; DMC, distant metastatic carcinoma. The proportion of well-differentiated thyroid carcinoma (papillary or follicular carcinoma) vs high-risk thyroid carcinoma (anaplastic, medullary, poorly differentiated, or distant metastatic carcinoma) is shown.
P < .001 for trend.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
